- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
HCC | Clinical
Case 1: Role of TARE in Unresectable Hepatocellular Carcinoma
June 24, 2022
Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.
Case 1: A 60-Year-Old With Unresectable Hepatocellular Carcinoma
June 24, 2022
Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.
Finn Reviews Options and Dosing for a Patient With Unresectable HCC
June 21, 2022
During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with hepatocellular cancer with a medical history of Crohn disease, cirrhosis, and variceal bleeding.
Studies in the Hepatocellular Carcinoma Space Leave Unanswered Questions
June 09, 2022
Amaia Lujambio Goizueta, PhD, discusses the unanswered questions currently circulating the hepatocellular carcinoma field.
Investigating the Role of the Notch Pathway in HCC Immune Resistance
May 17, 2022
Amaia Lujambio Goizueta, PhD, discusses a new approach to overcoming resistance to immunotherapy for patients with hepatocellular carcinoma.
Phase 2 Trial of GT90001 Plus Nivolumab Enrolls First Patient With Advanced HCC
May 08, 2022
The phase 2 clinical trial of the combination therapy, GT90001 and nivolumab, for the treatment of patients with advanced hepatocellular carcinoma has dosed its first patient.
Differences in Toxicity Based on Race in Nonsquamous NSCLC
May 03, 2022
Nino Balanchivadze, MD, FACP, discusses the rationale for evaluating toxicity based on race in the KEYNOTE-189 study.
Trials Initiated to Evaluate SRF388 Monoclonal Antibody in HCC and NSCLC
May 02, 2022
Surface Oncology announced the initiation of new trials of the investigational agent SRF388 in patients with hepatocellular carcinoma and non–small cell lung cancer.
FDA Grants Priority Review to Tremelimumab in Unresectable HCC
April 25, 2022
Priority review for a biologics license application has been granted by the FDA for tremelimumab as treatment of patients with unresectable hepatocellular carcinoma.
FDA Grants ODD Status to TTI-101 for Hepatocellular Carcinoma
April 25, 2022
The FDA has granted orphan drug designation to the STA3 inhibitor, TTI-101, for the treatment of hepatocellular carcinoma. The agent is currently being investigated in a phase 1 clinical trial.